期刊文献+

尼美舒利缓释片处方优化研究 被引量:7

Optimization of the Formula of Nimesulide Sustained-release Tablets
原文传递
导出
摘要 目的:优化尼美舒利缓释片的处方。方法:采用正交试验设计,以体外累积释放度为指标,以载药材料羟丙基甲基纤维素(HPMC)、乳糖、聚乙烯吡咯烷酮(PVP)K30无水乙醇溶液的处方用量作为影响因素,设计正交试验筛选缓释片的最佳处方,并进行处方验证试验。结果:优化处方为:HPMC100mg、乳糖50mg、5%PVPK30无水乙醇溶液3mL;以此处方制备的3批缓释片在12h累积释放度约为97%,未出现时滞、突释等现象,体外释药动力学符合零级方程。结论:尼美舒利缓释片处方合理,具有良好的缓释效果。 OBJECTIVE: To optimize the formula of Nimesulide sustained-release tablets. METHODS: The formula of Nimesulide sustained-release tablets was optimized by orthogonal design with accumulative release rate in vitro as index, and the amount of HPMC, lactose and PVP(K30) absolute alcohol solution as factors. Validation test was also conducted. RESULTS: The opti- mized formula was as follows: HPMC 100 mg, lactose 50 mg, 5% PVP K30 absolute alcohol solution 3 mL. The rate of in vitro accumulative drug release of 3 batches of samples was about 97% within 12 h, and there wash' t time-lag or sudden release phe- nomenon. The drug release in vitro could be well fitted with the zero-order equation. CONCLUSION: The formula of Nimesulide sustained-release tablets is reasonable. The prepared sustained-release tablets show well effect in vitro.
出处 《中国药房》 CAS CSCD 北大核心 2011年第9期823-825,共3页 China Pharmacy
基金 河南省重点学科开放课题(ZD200906) 河南省教育厅自然科学研究项目(2010B330002)
关键词 尼美舒利 缓释片 处方优化 累积释放度 正交试验 Nimesulide Sustained-release tablets Formula optimization Accumulative release rate Orthogonal experiment
  • 相关文献

参考文献7

  • 1Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview[J]. Inflamm Res, 1997, 46( 11 ) : 437.
  • 2Salvi GE, Lang NP. The effects of non-steroidal anti-infl- ammatory drugs (selective and non-selective) on the treatment of periodontal diseases[J]. Curr Pharm Des, 2005, 11(14):1 757.
  • 3Blanchi M, Broggini M. A randomized, double blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxid in osteoarthritis of the knee[J]. Drugs, 2003, 63(63) :37.
  • 4洪丽娟,潘卫三,潘裕生,周彩红,颜廷旭,聂淑芳.尼美舒利大鼠在体肠吸收动力学[J].中国新药与临床杂志,2009,28(2):130-133. 被引量:12
  • 5李萍,陈晓燕,尤孝庆,卢丹.尼美舒利缓释片的研制[J].中国医药工业杂志,2002,33(2):76-79. 被引量:6
  • 6郭曙刚,陈邦银,张汉萍.尼美舒利缓释片的研制和体外溶出度[J].中国医院药学杂志,2000,20(7):398-400. 被引量:10
  • 7Zhang Y, Huo M, Zhou J, et al. DDSolver. An add-in program for modeling and comparison of drug dissolution profiles[J].AAPSJ, 2010, 12(3): 263.

二级参考文献13

  • 1陈新梅,高晓黎.尼美舒利及其制剂研究现状[J].西北药学杂志,2003,18(6):284-285. 被引量:10
  • 2聂淑芳,潘卫三,李伟,杜玍妮.长春西汀的大鼠在体肠吸收研究[J].中国医药工业杂志,2005,36(10):625-628. 被引量:21
  • 3冯亮,蒋学华,周静,杨俊毅.三七皂苷R_1和人参皂苷Rg_1的大鼠在体肠吸收动力学研究[J].中国药学杂志,2006,41(14):1097-1102. 被引量:57
  • 4金美子.尼美舒利制剂的临床应用[J].现代医药卫生,2007,23(14):2194-2194. 被引量:6
  • 5陈新谦 金有豫.新编药物学(第14版)[M].北京:人民卫生出版社,1997.487.
  • 6BIANCHI M, BROGGINI M. A randomized, double blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee[J]. Drugs, 2003, 63 (63): 37.
  • 7STEWART BH, CHAN OH, LU RH, et al. Comparison of intestinal permeabilities determined inmuhiple in vitro and in situ models: relationship to absorption in humans[J]. Pharm Res, 1995, 12(5) : 693-699.
  • 8FAGERHOLM U, JOHANSSON M, LENNERNAS H. Comparision between permeability coefficients in rat and human jejunum [J]. Pharm Res, 1996, 13(9) : 336-342.
  • 91,Xavier R.Nimesulide:a selective cyclooxygenase 2 inhibitor antiinflamm atory[J].Drugs Today,1996,32:1
  • 102,Davis R,Brogden RN.Nimesulide an update of its pharmacodynamic and pha rmacokinetic properties and therapeutic efficacy[J].Drugs,1994,48(3):431

共引文献19

同被引文献52

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部